The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >
Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >
Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >
Let’s change the NGS market together – our global presence and partners world-wide
View Detail >
Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Oncology
Epigenomics Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et…
Investig Clin Urol Germline pathogenic variants in unselected Korean men with prostate cancer So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate…
Scientific Reports Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers Lee J, Ham JY, Park HY, Jung JH, Kim WW,…
BMC Medical Genomics A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel…
Leuk Lymphoma Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma Lee Y, Yun J, Jeong D, Ryu S, Kwon SR, Yun H, et al.…
Nat Commun Spatial epitranscriptomics reveals A-to-I editome specific to cancer stem cell microniches Lee AC, Lee Y, Choi A, Lee HB, Shin K, Lee H, et al. Spatial epitranscriptomics reveals…
In Vivo Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer Lee J, Kim JM, Lee YH, Chong GO, Lee NY, Lee IH, et al.…
Blood Res A rare case of primary plasma cell leukemia exhibiting the small-cell variant of plasma cells Kim JA, Shin WY, Kim J, Bang HI, Yoon SY, Park R. A…
In Vivo A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN) Lee YJ, Seol A,…
Nat Commun A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer Lee CK, Rha SY, Kim HS, Jung M, Kang B, Che…
